Ayala Pharmaceuticals, Inc. has heralded data from a Phase II/III trial on its investigational drug, AL102, for desmoid tumors, although investors seem concerned that the Israel-headquartered biotech has much to do to compete with rival SpringWorks Therapeutics Inc.'s nirogacestat.
The company unveiled updated interim results at the European Society for Medical Oncology (ESMO) congress in Paris from part A...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)